title: [Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation].
abstract: OBJECTIVE
  to evaluate the significance of soluble ST2-receptor (sST2) concentrations in patient (pts) risk stratification in with acute decompensated heart failure (ADHF) during long-term follow-up period.
  
  
  METHODS
  In the prospective single-center study were included 159 pts with ADHF III-IV FC NYHA. Blood samples to determine NT-proBNP, sST2, hsTnT concentration were collected at the admission and at discharge from the hospital, and after 3, 6 and 12 months of follow-up. The combined primary end point of the trial included cardiovascular (CV) death, hospitalization due to HF, episodes of HF deterioration needed additional i/v diuretics and CV death with successful resuscitation.
  
  
  RESULTS
  At admission all pts had elevated biomarker concentrations: NT-proBNP - 3615.5 (1578.0; 6289.3)pg/ml, sST2 - 60,49 (41.95; 92.87) ng/ml, hsTnT - 29.95 (21.85; 49.63) pg/ml; and at discharge: NT-proBNP - 2165.5 (982.7; 4221,2) pg/ml (%=-38,27 (-49.7; -24.34)%, p<0.0001), sST2 - 38.43 (24.67; 63.72) ng/ml (%=-30,13 (-42,07; -17,64)%, p<0,0001), and hsTnT - 28,37(21.29; 46.6) pg/ml. During 1-year follow-up 56 pts (35.2 %) had 78 (49.1%) cardiovascular events. Biomarker concentrations in low risk pts (without CV events) were significantly lower compared with high risk pts (who have CV events). At the discharge NT-proBNP and sST2 concentrations had the most predictive capacity relatively the primary end point during 1-year follow-up: AUC=0.727 (95% CI 0.637-0.816), <0,0001, and AUC=0,768 (95% CI 0.682-0.854), <0.0001, respectively. Maximally sST2 values were predictive for 180 days period of follow-up: AUC=0,809 (95% CI 0.726-0.921; <0,0001). Lack of NT-proBNP and sST2 concentrations decrease below 1696 pg/ml and 37.8 ng/ml respectively were associated with the highest risk of CV events (HR 4.41 [95% CI 1.41-9.624], p<0,0001 and HR 6.755 [95% CI 3.026- 15.082], p<0.0001, respectively). Changes of sST2 concentration during the period of pts hospitalization were also prognostically important, AUC=0.696 (0.596-0.796); p<0.0001. And pts with insufficient degree of sST2 concentrations reduction during the period of hospitalization (% <-28,3%) had the worst short-term and long-term prognosis [HR 3.68 (95% CI 2.05-6.64), p<0.0001]. Values of sST2 at the discharge were the most significant independent predictor of CV events in long-term follow-up (=0.519, p<0.0001). 91,8% of pts without CV events in the study had sST2 and NT-proBNP levels below 37.8 ng/ml and 1696 pg/ml respectively after 3, 6 and 12 months of follow-up.
  
  
  CONCLUSIONS
  The values of soluble ST2-receptor over 37.8 ng/ml and NT-proBNP over 1696 pg/ml at the discharge from the hospital reflects the adverse prognosis in patients with ADHF. Serial determination of sST2 and NT-proBNP concentrations after discharge from the hospital indicates the necessity of reduction the levels of these biomarkers below the cut-off values (<37.8ng/mL and <1696pg/ml respectively) in pts with ADHF in long-term follow-up period.
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.|National Research Center for Preventive Medicine, Moscow, Russia.
authors.forename: A A
authors.initials: AA
authors.lastname: Skvortsov
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.|National Research Center for Preventive Medicine, Moscow, Russia.
authors.forename: V N
authors.initials: VN
authors.lastname: Protasov
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.|National Research Center for Preventive Medicine, Moscow, Russia.
authors.forename: O Yu
authors.initials: OY
authors.lastname: Narusov
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.|National Research Center for Preventive Medicine, Moscow, Russia.
authors.forename: D E
authors.initials: DE
authors.lastname: Koshkina
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.|National Research Center for Preventive Medicine, Moscow, Russia.
authors.forename: S N
authors.initials: SN
authors.lastname: Nasonova
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.|National Research Center for Preventive Medicine, Moscow, Russia.
authors.forename: V P
authors.initials: VP
authors.lastname: Masenko
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.|National Research Center for Preventive Medicine, Moscow, Russia.
authors.forename: S N
authors.initials: SN
authors.lastname: Tereschenko
mesh_terms: D015415:Biomarkers; D006333:Heart Failure; D006801:Humans; D020097:Natriuretic Peptide, Brain; D010446:Peptide Fragments; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; D020097:Natriuretic Peptide, Brain
keywords: NT-proBNP; chronic heart failure; decompensated heart failure; risk stratification; soluble ST2 receptor